SecBot SecBot
8-K ·Filed Jul 6, 2026

VRTX

VERTEX PHARMACEUTICALS INC / MA
BULLISH
Impact 7/10
Horizonweeks Processed4mo ago SEC0001193125-26-296710
8-K material event: Items 1.01
Actionable Insight ▲ Bullish

Monitor the special shareholder meeting and regulatory (HSR) clearance timeline for Q3 2026 close. Vertex's large-cap profile and all-cash, non-contingent financing limit downside risk, but integration and pipeline execution risks remain. Watch for any competing bids or regulatory pushback.

DirectionBullish
Confidencehigh
Horizonweeks

Drugs in focus

VRTX drug pipeline →

atumelnant

▲ Bullish Named in this 8-K
Impact
Phase
Phase 3 (CAH); Phase 1b/2a (ADCS)
Time to market
Estimated 2028 for CAH if Phase 3 succeeds (assuming ~1.5-2 year Phase 3 enrollment + regulatory review); ADCS indication is earlier-stage.
Next catalyst
None dated

What to watchWatch for CALM-CAH enrollment completion updates and any topline readout timeline guidance on upcoming quarterly earnings calls. The Phase 3 data is the make-or-break event, but the stock already has a commercial-stage floor from PALSONIFY revenue, reducing doomsday downside. Competitor Neurocrine's CRENESSITY is approved first, but early data suggests atumelnant may have a superior efficacy profile.

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$522.25
T+0 close · Jul 6, 2026 · via day close
Latest settled
+0.11%
T+60 · $522.81
Vs SPY
−1.89%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 7 $522.25entry
  2. T+1 · 4mo ago −4.56%α −4.25% · $498.43
  3. T+5 · 4mo ago −8.80%α −9.35% · $476.31
  4. T+20 · 4mo ago −9.87%α −11.20% · $470.72
  5. T+60 · 7w ago +0.11%α −1.89% · $522.81
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Vertex Pharmaceuticals announced a definitive agreement to acquire Crinetics Pharmaceuticals for $85.00 per share in cash, representing a total equity value of $10.0 billion ($8.8 billion net of cash). The deal adds PALSONIFY (approved, launched oral therapy for acromegaly) and atumelnant (Phase 3 oral ACTH receptor antagonist for congenital adrenal hyperplasia) to Vertex's pipeline, which it expects to generate over $5 billion in combined peak annual revenue. Vertex funded the transaction with cash on hand and a fully committed $4.5 billion bridge financing facility from Bank of America and Morgan Stanley; the deal is expected to close in Q3 2026 and become accretive to non-GAAP operating income in 2029.

Key Financial Metrics

Deal Value
$10.0B
Deal Type
acquisition

Key Facts

  • Vertex acquired Crinetics for $85.00 per share in cash, with a $10.0B equity valuation ($8.8B net of cash).
  • The deal adds PALSONIFY, the first and only once-daily oral therapy for acromegaly (launched Oct. 2025, FDA and EMA approved), and atumelnant, a Phase 3 oral ACTH receptor antagonist for congenital adrenal hyperplasia (CAH).
  • Vertex expects the combined assets to generate over $5 billion in annual peak revenue and the deal to become accretive to non-GAAP operating income in 2029.
  • The merger is expected to close in Q3 2026, subject to Crinetics shareholder approval, HSR clearance, and other customary conditions.
  • Vertex secured a $4.5 billion fully committed 364-day bridge loan facility from Bank of America and Morgan Stanley to finance the merger; the deal is not conditioned on financing.
  • The termination fee payable by Crinetics to Vertex under specified circumstances is $350,474,425.

Financial Impact

$10.0B equity value ($8.8B net of cash); expects >$5B in combined peak annual revenue from acquired assets

revenueearnings_profiledebtpipeline_value

Risk Factors

  • Failure to obtain Crinetics shareholder approval or regulatory clearances (HSR, foreign)
  • Integration challenges or slower-than-expected commercial uptake of PALSONIFY and atumelnant
  • Execution risk in R&D pipeline for atumelnant and other early-stage assets
  • Potential termination fee of $350.5M if the deal fails under certain circumstances

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
83% bullish (40 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-296710
Document: d113650dex991.htm0001193125-26-296710
Document: 0001193125-26-296710-index-headers.html0001193125-26-296710
Document: 0001193125-26-296710-index.html0001193125-26-296710
Document: 0001193125-26-296710.txt0001193125-26-296710

Track record

21 reports on VRTX

Performance horizon

3 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +10.87% at T+60 after the Feb 25, 2026 report. 3 of 3 went positive at some point.

Filters
  1. Nov 16, 2026today Insider Cluster Neutral 2/10 Entry $537.79 Now $531.45 −1.18% settles Nov 24
  2. Nov 16, 20261d ago 144 Neutral 2/10 Entry $543.10 Now $531.45 −2.15% settles Nov 23
  3. Nov 16, 20261d ago 144 Neutral 1/10 Entry $544.98 Now $531.45 −2.48% settles Nov 23
  4. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $542.00 Now $531.45 −1.95% settles Nov 23
  5. Nov 12, 20265d ago 144 Neutral 2/10 Entry $542.62 Now $531.45 −2.06% settles Nov 19
  6. Nov 6, 202611d ago 144 Neutral 2/10 Entry $547.09 to $538.60 Now $531.45 −2.86% ▼ −1.55% −4.15% vs SPY
  7. Nov 2, 202614d ago 8-K Bullish 6/10 Entry $530.76 to $547.89 Now $531.45 +0.13% ▲ +3.23% +3.81% vs SPY
  8. Oct 22, 202626d ago 3 Neutral 2/10 Entry $523.93 to $558.88 Now $531.45 +1.44% ▲ +6.67% +7.23% vs SPY
  9. Oct 20, 202628d ago 8-K Neutral 2/10 Entry $524.52 to $521.03 Now $531.45 +1.32% ▼ −0.67% −0.22% vs SPY
  10. Oct 16, 20264w ago Institutional Cluster Bullish 4/10 Entry $500.36 to $517.49 Now $531.45 +6.21% ▲ +3.42% +3.57% vs SPY
Showing 10 of 21

US Market Status

Market Open · Closes in 43m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 7, 2026